Chiusura precedente | 16,17 |
Aperto | 18,43 |
Denaro | 0,00 x N/D |
Lettera | 0,00 x N/D |
Min-Max giorno | 18,43 - 18,43 |
Intervallo di 52 settimane | 18,43 - 18,43 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 5,389M |
Beta (5 anni mensile) | 0,62 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,36 |
Prossima data utili | 31 ott 2022 - 04 nov 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update. “It has been a busy first half of the year as we continue in ou
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and Chief Operating Officer. Dr. Manion will be responsible for overseeing day-to-day operations, continuing to develop Aclaris’ infrastructure and
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York. Management will be available June 8th for 1x1 meetings. A live webcast of the fi